Virtus LifeSci Biotech Clinical Trials ETF
17 hedge funds and large institutions have $8.24M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
44% less capital invested
Capital invested by funds: $14.7M → $8.24M (-$6.46M)
Holders
17
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$569K | |
| 2 | +$505K | |
| 3 | +$427K | |
| 4 |
CCP
Cardan Capital Partners
Denver,
Colorado
|
+$47.8K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$5.19K |
Top Sellers
| 1 | -$1.63M | |
| 2 | -$783K | |
| 3 | -$638K | |
| 4 |
AWM
AE Wealth Management
Topeka,
Kansas
|
-$262K |
| 5 |
LPL Financial
San Diego,
California
|
-$207K |